Loading
Enveric Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 19 Sept 2023.
Enveric Biosciences, Inc.: what insiders have been doing
Enveric Biosciences, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 7 filings came from 7 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
No insider has bought Enveric Biosciences, Inc. shares on the open market in the past twelve months. The median gap between a trade and its publication by SEC (Form 4) is 7 days. Section 16 rules allow two business days to file each Form 4.
Compared with its exchange (5,458 companies, median 22 filings), a count of 7 filings is below the norm. Over the whole record (from 2016), the tally stands at 5 purchases and no sales.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
40
Thresholds
n/a
Buy Volume
€2,012
5 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.51
Analyst consensus
Income statement
EBITDA-US$8.6M
Net income-US$8.8M0.0% margin
Valuation
P/Book0.6x
Beta1.11
Balance sheet & cash
Market capUS$6.1M
Free Cash Flow-US$8.1M
Profitability & ownership
ROE-183.1%
ROA-96.7%
% insiders10.8%
% institutions3.3%
Last declaration on 30 December 2025
Declarations40 total
7,633 shares0Common StockSEC:0001193125-25-337178:0
60,296 shares0Common StockSEC:0001193125-25-337175:0
7,633 shares0Common StockSEC:0001193125-25-337172:0
40,198 shares0Common StockSEC:0001193125-25-337171:0
7,633 shares0Common StockSEC:0001193125-25-337184:0
7,633 shares0Common StockSEC:0001193125-25-337182:0
7,633 shares0Common StockSEC:0001193125-25-337179:0
74,150 shares0Common StockSEC:0001415889-25-012679:0
24,717 shares0Common StockSEC:0001415889-25-012678:0
98,866 shares0Common StockSEC:0001415889-25-012677:0
27,845 shares0Common StockSEC:0001415889-24-025063:0
47,733 shares0Common StockSEC:0001415889-24-025059:0
47,733 shares0Common StockSEC:0001415889-24-025057:0
161,633 shares0Common StockSEC:0001415889-24-025052:0
40,000 shares0Common StockSEC:0001415889-24-025050:0
47,733 shares0Common StockSEC:0001415889-24-025055:0
47,733 shares0Common StockSEC:0001415889-24-025061:0
100,000 shares0Common StockSEC:0001415889-24-025048:0
60,000 shares0Common StockSEC:0001415889-24-005251:0
50,000 shares0Common StockSEC:0001415889-24-005253:0
100,000 shares0Common StockSEC:0001415889-24-005259:0
1,000 shares@ US$2.14100.0% of flowCommon StockSEC:0001415889-23-013430:0
Canonical exit: 14 Dec 2023 (T+90)
26,500 shares0Common StockSEC:0001493152-23-007662:0
17,000 shares0Common StockSEC:0001493152-23-002802:0
12,000 shares0Common StockSEC:0001493152-23-002801:0
25 of 40 declarations
About Enveric Biosciences, Inc.
Enveric Biosciences, Inc. is a U.S.-listed biotechnology company traded on the NASDAQ under the ticker ENVB. The company is headquartered in Cambridge, Massachusetts, United States, and is focused on neuroscience and mental health drug development. Enveric states that it is a development-stage company and currently markets no products, which means the investment case is driven by pipeline progress rather than commercial sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/890821/000149315226016546/formars.pdf))
The company’s strategic narrative has become increasingly centered on next-generation neuroplastogenic small molecules for neuropsychiatric disorders. Enveric’s proprietary discovery engine, The Psybrary™, is designed to generate novel compounds for specific mental health indications. Its lead program is EB-003, a small-molecule candidate being developed for difficult-to-treat mental health conditions. Recent company updates indicate that EB-003 has advanced through pre-IND work, dose-range finding studies, and additional preclinical testing, with Enveric aiming to move toward an IND submission and first-in-human studies in 2026. ([enveric.com](https://www.enveric.com/))
Read moreShow less
From a competitive standpoint, Enveric is not trying to win on scale; it is trying to win on scientific novelty, intellectual property, and pipeline differentiation. Management has emphasized a broad patent portfolio around rationally designed neuroplastogens, including EVM401 and EVM-301 series compounds, as a way to build a durable moat in a crowded and highly specialized field. This matters because the neuropsychiatric drug landscape is competitive, and the company will need to prove that its chemistry can translate into meaningful clinical benefit, acceptable safety, and regulatory traction. ([enveric.com](https://www.enveric.com/))
Recent business highlights also suggest a pragmatic capital-allocation approach. Enveric has pursued out-licensing transactions for selected non-core assets, helping it extract value from parts of the portfolio while focusing resources on its main neuropsychiatric programs. The company has also highlighted positive preclinical data, chemistry/manufacturing progress, and patent awards or allowances for newer compound series. For investors in France, Belgium, and Switzerland, Enveric should be viewed as a high-risk, high-upside U.S. biotech story whose valuation will be highly sensitive to regulatory milestones, clinical readouts, and financing needs rather than current revenues. ([enveric.com](https://www.enveric.com/news/enveric-biosciences-reports-financial-results-and-provides-corporate-update-for-fourth-quarter-and-fiscal-year-ended-2024/))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
